암 진단 시장 : 암 유형, 기술, 검체 유형, 연령층, 용도, 최종 사용자별 - 세계 시장 예측(2026-2032년)

The Cancer Diagnostics Market is projected to grow by USD 112.67 billion at a CAGR of 12.26% by 2032.

Cancer Diagnostics Executive Summary

Cancer diagnostics is moving from episodic, symptom-led testing toward earlier, molecularly informed detection across screening, diagnosis, treatment selection, and recurrence monitoring. The clinical need is substantial: the World Health Organization's IARC GLOBOCAN 2022 estimates about 20 million new cancer cases and 9.7 million cancer deaths worldwide, with the burden expected to rise sharply as populations age and exposure to preventable risk factors persists.

Demand is being shaped by high-volume pathology, imaging, companion diagnostics, next-generation sequencing, liquid biopsy, immunohistochemistry, cytology, HPV testing, and point-of-care testing. Health systems are prioritizing diagnostics that shorten time to diagnosis, improve tumor characterization, support precision oncology, and expand access to guideline-recommended screening for breast, cervical, colorectal, lung, and prostate cancers.

Transformative Shifts in the Cancer Diagnostics Landscape

The cancer diagnostics landscape is being transformed by the convergence of molecular testing, digital pathology, advanced imaging, and decentralized sample collection. Tumor profiling is increasingly embedded in routine oncology workflows because targeted therapies and immunotherapies often require validated biomarkers such as EGFR, ALK, HER2, BRCA, MSI, PD-L1, and NTRK.

At the same time, laboratories face pressure to improve turnaround time, reimbursement evidence, sample traceability, and interoperability with electronic health records. The shift from single-gene assays to multi-gene panels and comprehensive genomic profiling is raising expectations for analytical validity, clinical utility, external quality assessment, and standardized reporting across hospital laboratories, reference laboratories, and oncology networks.

Cumulative Impact of Artificial Intelligence on Cancer Diagnostics

Artificial intelligence is having a cumulative impact across radiology, pathology, genomics, and workflow orchestration. In imaging, AI supports lesion detection, triage, segmentation, and longitudinal comparison, while in pathology it helps quantify biomarkers, prioritize suspicious slides, and improve consistency in high-volume review.

Regulators are increasingly evaluating AI-enabled medical devices, and the U.S. FDA has listed hundreds of authorized AI and machine-learning-enabled devices, with radiology representing the largest category. For cancer diagnostics, the practical value of AI depends on prospective validation, bias monitoring, cybersecurity, explainability, human oversight, and integration into clinician-supervised decision pathways rather than standalone automation.

Key Regional Insights Across Cancer Diagnostics

Asia-Pacific is becoming a major opportunity base as China, India, Japan, South Korea, and Australia invest in oncology infrastructure, molecular laboratories, digital health, and population screening. North America remains a leading region for cancer diagnostics due to high oncology spending, established screening programs, broad adoption of companion diagnostics, and mature regulatory pathways for in vitro diagnostics and laboratory-developed tests.

Latin America is improving access through public-private diagnostic networks, with Brazil and Mexico acting as important demand centers for pathology, imaging, HPV testing, and molecular oncology. Europe is shaped by national cancer plans, organized screening, IVDR implementation, and cross-border research networks, while the European Health Data Space is designed to strengthen data-driven oncology innovation. The Middle East is expanding precision medicine through tertiary cancer centers, digital health programs, and national genomics initiatives, while Africa's priority is scalable access to pathology, HPV testing, imaging, and basic oncology diagnostics in line with WHO cancer control goals.

Key Group Insights for Global Cancer Diagnostics Adoption

ASEAN is focused on affordable cancer screening, laboratory capacity, pathology workforce development, and regional referral networks to improve access across diverse health systems. The GCC is investing heavily in precision oncology, digital health, centralized specialty care, and national genomics initiatives, strengthening demand for advanced molecular diagnostics and AI-enabled imaging workflows.

The European Union is pivotal because IVDR, cancer screening recommendations, and Europe's Beating Cancer Plan influence diagnostic quality, evidence generation, and market access. BRICS countries represent large-volume growth driven by cancer burden, expanding middle-class access, public oncology investment, and domestic diagnostic manufacturing. The G7 anchors high-value adoption through advanced oncology reimbursement, clinical trial density, biomarker-driven therapy use, and regulatory science, while NATO countries overlap significantly with major diagnostic innovation hubs in North America and Europe, supporting resilient supply chains for reagents, imaging equipment, semiconductors, cloud infrastructure, and cybersecurity-enabled health data systems.

Key Country Insights Shaping Cancer Diagnostics Demand

The United States leads in companion diagnostics, oncology genomics, liquid biopsy innovation, and AI-enabled imaging, supported by large cancer centers and payer scrutiny around clinical utility. Canada emphasizes equitable screening and provincial laboratory networks, while Mexico and Brazil are expanding access to pathology, immunohistochemistry, HPV testing, imaging, and molecular oncology within mixed public-private systems.

The United Kingdom, Germany, France, Italy, and Spain are advancing national cancer strategies, genomics programs, organized screening, and digital pathology adoption, while Russia maintains demand for imaging and pathology modernization. China is scaling domestic IVD innovation and oncology testing capacity; India is prioritizing affordable diagnostics, HPV testing, and tertiary cancer care expansion; Japan and South Korea remain leaders in precision oncology, companion diagnostics, and high-quality imaging; and Australia combines strong screening participation, research infrastructure, and digital health adoption.

Actionable Recommendations for Cancer Diagnostics Leaders

Industry leaders should prioritize clinically validated diagnostics that demonstrate measurable improvements in detection, staging, therapy selection, recurrence monitoring, or care pathway efficiency. Evidence packages should include analytical performance, real-world clinical utility, health-economic impact, and workflow fit for oncologists, pathologists, radiologists, laboratory directors, and public screening programs.

Organizations should also invest in interoperable platforms, AI governance, decentralized sample logistics, cybersecurity, and regulatory-ready quality systems. Strategic partnerships with cancer centers, payers, biobanks, public health agencies, and screening programs can accelerate adoption, while tiered pricing, local training, and regional manufacturing can improve access in emerging markets.

Research Methodology for Cancer Diagnostics Intelligence

This executive summary is based on secondary research from authoritative public sources, including WHO, IARC GLOBOCAN, national cancer institutes, regulatory agencies, peer-reviewed oncology literature, clinical guideline bodies, and public health program documentation. Market interpretation considers epidemiology, diagnostic guidelines, technology adoption, reimbursement structures, regulatory requirements, and regional healthcare capacity.

The analysis triangulates data across disease burden, screening participation, installed diagnostic infrastructure, regulatory developments, precision medicine adoption, and evidence standards for oncology testing. Insights are validated through consistency checks across clinical evidence, policy direction, and technology deployment patterns to support decision-making for manufacturers, laboratories, investors, and healthcare providers.

Conclusion: Cancer Diagnostics as a Precision Oncology Engine

Cancer diagnostics is becoming a central pillar of precision oncology, public health screening, and value-based cancer care. Momentum is being driven by rising cancer incidence, biomarker-linked therapies, AI-enabled interpretation, and expanding access to molecular, pathology, cytology, and imaging-based diagnostics.

The most competitive organizations will combine scientific validity, operational scalability, regulatory discipline, data security, and equitable access strategies. As health systems seek earlier detection and more personalized treatment, cancer diagnostics will remain one of the most strategically important segments of global healthcare.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Cancer Diagnostics Market, by Cancer Type

• 7.1. Hematological Cancers
  • 7.1.1. Leukemia
  • 7.1.2. Lymphoma
  • 7.1.3. Multiple Myeloma
• 7.2. Solid Tumors
  • 7.2.1. Breast Cancer
  • 7.2.2. Colorectal Cancer
  • 7.2.3. Lung Cancer
  • 7.2.4. Prostate Cancer

8. Cancer Diagnostics Market, by Technology

• 8.1. Flow Cytometry
  • 8.1.1. Cell Sorting
  • 8.1.2. Multiparameter Flow Cytometry
• 8.2. Imaging
  • 8.2.1. Computed Tomography
  • 8.2.2. Magnetic Resonance Imaging
  • 8.2.3. Positron Emission Tomography
  • 8.2.4. Ultrasound
• 8.3. Immunohistochemistry
  • 8.3.1. Chromogenic
  • 8.3.2. Fluorescent
• 8.4. In Situ Hybridization
• 8.5. Molecular Diagnostics
  • 8.5.1. Microarray
  • 8.5.2. PCR
  • 8.5.3. Sequencing

9. Cancer Diagnostics Market, by Specimen Type

• 9.1. Tissue
• 9.2. Blood
• 9.3. Bone Marrow
• 9.4. Urine
• 9.5. Saliva

10. Cancer Diagnostics Market, by Age Group

• 10.1. Pediatric
• 10.2. Adult
• 10.3. Geriatric

11. Cancer Diagnostics Market, by Application

• 11.1. Screening & Early Detection
• 11.2. Initial Diagnosis
• 11.3. Prognosis & Risk Stratification
• 11.4. Therapy Selection
• 11.5. Treatment Monitoring
• 11.6. Recurrence Monitoring

12. Cancer Diagnostics Market, by End User

• 12.1. Ambulatory Care
• 12.2. Diagnostic Laboratories
• 12.3. Hospitals
• 12.4. Research Institutes

13. Cancer Diagnostics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Cancer Diagnostics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Cancer Diagnostics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Concentration Analysis, 2025
  • 16.1.1. Concentration Ratio (CR)
  • 16.1.2. Herfindahl Hirschman Index (HHI)
• 16.2. Recent Developments & Impact Analysis, 2025
• 16.3. Product Portfolio Analysis, 2025
• 16.4. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. Agilent Technologies, Inc.
• 17.3. Becton, Dickinson and Company
• 17.4. Bio-Rad Laboratories, Inc.
• 17.5. bioMerieux SA
• 17.6. Canon Medical Systems Corporation
• 17.7. Danaher Corporation
• 17.8. DiaSorin S.p.A.
• 17.9. F. Hoffmann-La Roche Ltd
• 17.10. Fujifilm Corporation
• 17.11. GE HealthCare Technologies Inc.
• 17.12. Hologic, Inc.
• 17.13. Illumina, Inc.
• 17.14. Myriad Genetics, Inc.
• 17.15. NeoGenomics Laboratories, Inc.
• 17.16. PerkinElmer, Inc.
• 17.17. QIAGEN N.V.
• 17.18. Quest Diagnostics Incorporated
• 17.19. Siemens Healthineers AG
• 17.20. Sysmex Corporation
• 17.21. Thermo Fisher Scientific Inc.